Sep. 09, 2025
WERVIC, a leader in companion animal health solutions, today announced the official launch of WERVIC Firocoxib Tablets, a prescription non-steroidal anti-inflammatory drug (NSAID) tailored to address pain and inflammation in dogs. The new product aims to improve quality of life for canines struggling with chronic osteoarthritis discomfort or recovering from surgical procedures, such as neutering or orthopedic interventions.
Osteoarthritis affects millions of dogs globally, particularly senior or large-breed companions, while post-surgical pain often hinders recovery and limits a dog’s mobility. WERVIC Firocoxib Tablets directly addresses these challenges by focusing on COX-2, an enzyme linked to pain and inflammation, without disrupting COX-1—a key protector of gastrointestinal and renal health.
“For pet parents, watching a dog struggle with pain—whether from aging joints or post-surgery soreness—is heartbreaking,” said [Your Name], [Job Title] at [Your Company Name]. “WERVIC was developed to not only relieve discomfort but also let dogs return to the activities they love: zoomies in the yard, cuddles on the couch, and playful moments with their families.”
Rigorous testing and veterinary input have shaped WERVIC Firocoxib Tablets’ core advantages, designed to balance performance with pet well-being:
As a prescription medication, WERVIC Firocoxib Tablets require adherence to veterinary guidance to ensure pet safety. [Your Company Name] emphasizes the following best practices:
WERVIC Firocoxib Tablets are now available exclusively through licensed veterinary clinics nationwide. Pet parents interested in the product should consult their vet to determine if it is right for their dog. For additional information—including technical resources for veterinarians—visit https://www.victorypharmgroup.com/.
“Our mission is to create solutions that prioritize both efficacy and pet safety,”“With WERVIC, we’re giving pet parents a reliable way to help their dogs live happier, more comfortable lives—one dose at a time.”